Donate Fighting Coronavirus
Physical World
Partners in Science
Gift Opportunities
project based fundraising
The Weizmann Effect
Founded in 1944, the American Committee for the Weizmann Institute of Science develops philanthropic support for the Weizmann Institute in Israel, and advances its mission of science for the benefit of humanity.
The Weizmann Institute's fundamental research has led to discoveries and applications with a major impact on the scientific community and on the quality of life for millions worldwide.
Join a community of dedicated people who share the Weizmann Institute's commitment to shaping a better world through science.
Learn about the Weizmann Institute's latest groundbreaking discoveries and the American Committee's activities across the country.
The Curiosity Review
Popular science for the curious-minded: The Curiosity Review brings discovery to life.
Fighting Coronavirus Donate
How Cancers Hurt Themselves to Hurt Immune Cells More
REHOVOT, ISRAEL—December 16, 2020—Cancers like melanoma are hard to treat, not least because they have a varied bag of tricks for defeating or evading treatments. Now, a combined research effort by the Weizmann Institute of Science...
A New Approach to Tailoring Cancer Therapy: Tapping Into Signaling Activities in Cancer Cells
REHOVOT, ISRAEL—July 16, 2020—Choosing the right drug for each cancer patient is key to successful treatment, but physicians currently have few reliable pointers to guide them in designing treatment protocols. Researchers at the Weizmann Institute of Science and the Broad Institute of MIT and Harvard have now developed a new method...
Cells Inside Cells: The Bacteria That Live in Cancer Cells
REHOVOT, ISRAEL—June 2, 2020—Cancer cells are comfy havens for bacteria. That conclusion arises from a rigorous study of over 1,000 tumor samples of different human cancers.
Predicting Immunotherapy Success
REHOVOT, ISRAEL—February 18, 2020—One of the frustrations with anti-cancer therapy is that no one drug fits all: Most work well in some people but have little effect in other patients with the same type of cancer. This is as true of the newer immunotherapy treatments as it is of older types of chemotherapy. Weizmann Institute of Science researchers have now identified new markers that can help predict which patients have a better chance for a positive response to immunotherapy treatments. Their findings were reported in Nature Communications.
A New Route to Blocking Children's Bone Cancer
Ewing sarcoma is a bone cancer that appears mainly in teenagers. Caused by a single defective gene, once it spreads to distant organs it is hard to treat. Researchers at the Weizmann Institute of Science have now discovered molecular interactions underlying Ewing sarcomas and proposed a potential treatment that has shown promise in a study in mice. These findings were published in Cell Reports.
Cancer Protocols: A New Approach to Predicting Treatment Outcomes
Diversity – at least among cancer cells – is not a good thing. Now, research from the Weizmann Institute of Science shows that in melanoma, tumors with cells that have differentiated into more diverse subtypes are less likely to be affected by the immune system, thus reducing the chance that immunotherapy will be effective. The findings of this research, which were published in Cell, may provide better tools for designing personalized protocols for cancer patients, as well as pointing toward new avenues of research into anti-cancer vaccines.
TOOKAD®, Invented at the Weizmann Institute of Science, Gains European Approval for Prostate Cancer
Steba Biotech, a privately owned company, has, in collaboration with scientists at the Weizmann Institute of Science, conducted extensive research and development on the prostate cancer treatment TOOKAD® – and now has received marketing authorization to make it available in 31 European countries. Following this regulatory approval, the first patients are currently being treated in top Israeli, German, English, and Italian medical centers.
Profiling a Killer in Warm Blood
Cancer arises when cells lose control. Deciphering the "blueprint" of cancer cells – outlining how cancer cells hijack specific pathways for uncontrolled proliferation – will lead to more efficient ways to fight it. Now, in a joint effort, scientists from the Weizmann Institute of Science and clinicians from major hemato-oncology departments in Israel have successfully created detailed profiles of myeloma cancer in both pre-cancer stages, in newly diagnosed multiple myeloma patients, as well as post-treatment and relapse. These detailed blueprints will help in future precision diagnosis and treatment of this disease.
Toward an "Ultra-Personalized" Therapy for Melanoma
With new immunotherapy treatments for melanoma, recovery rates have risen dramatically – in some cases to around 50%. But they could be much higher. A new study led by researchers at the Weizmann Institute of Science showed, in lab dishes and animal studies, that a highly personalized approach could help the immune cells improve their ability to recognize the cancer and kill it. The results of this study were published in Cancer Discovery.
Learn more about remarkable Weizmann Institute achievements that are enhancing and transforming our lives.
Start a Project-Based Fundraiser
Support a life-changing project, and use the power of crowdfunding to inspire others to join you.
Get the latest news and breakthroughs from the Weizmann Institute of Science.
Enriching Education
Protecting Our Planet
Improving Health & Medicine
Exploring the Physical World
Blog: Curiosity Review
News & Media Careers Contact Us Privacy Policy Gift Acceptance Policy Financial Information
©2021 American Committee for the Weizmann Institute of Science